FDA Drug Chief Faces Ethics Questions Over Friend’s Antidepressant Warning Push

The FDA's top drug regulator is attempting to hire a close associate who wants to add new pregnancy warnings to antidepressants, raising conflict of interest concerns. Medical experts worry the proposed warnings could lead pregnant women to stop necessary medications.

WASHINGTON — Federal health officials are raising ethics concerns about the Food and Drug Administration’s chief drug regulator, Dr. Tracy Beth Hoeg, who is attempting to bring on board a personal associate pushing for controversial new pregnancy warnings on antidepressants, according to an Associated Press investigation.

The associate, Dr. Adam Urato, specializes in maternal-fetal medicine and has submitted a formal request asking the FDA to place a prominent boxed warning on SSRI antidepressants. His proposal claims these widely-prescribed depression medications may cause pregnancy losses and brain development issues in unborn children that could result in autism and other conditions.

Sources with knowledge of internal FDA operations tell the AP that this labeling change has become Hoeg’s primary focus. She maintains regular communication with Urato and is actively pursuing his employment at the agency, according to these individuals who requested anonymity due to the sensitive nature of the matter.

FDA personnel consider Hoeg’s personal connection to Urato a significant ethical violation that would typically require her to step away from any decisions involving his proposal. However, she continues to personally expedite the agency’s evaluation of her associate’s request, sources indicate.

Medical professionals outside the agency express skepticism about the proposal, noting it depends on questionable evidence from animal testing and limited human studies. They worry that additional FDA warnings might prompt expectant mothers to abandon necessary treatment, creating dangerous health consequences from unmanaged depression.

“A black box warning is a big red flag with both practitioners and patients,” said Dr. Jennifer Payne, a University of Virginia reproductive psychiatrist. “What’s missing in this petition is an understanding of the risks of maternal mental illness during pregnancy, not just to the woman, but to the pregnancy and ultimately the infant.”

SSRI medications encompass many of the most commonly prescribed depression treatments, including brand names like Prozac, Paxil, and Zoloft, along with their generic versions.

Federal data shows more than 15% of American women — approximately 26 million individuals — use depression medication. Current medical guidelines indicate these drugs are typically safe for pregnant women and should only be stopped following thorough discussion with healthcare providers.

During an autumn presentation to senior FDA drug administrators, Hoeg discussed the SSRI proposal as her own work. Staff members who examined her presentation materials discovered they had been prepared by Urato, according to sources who spoke with the AP. This incident was initially disclosed by Stat News.

In a Wednesday email response, Urato described Hoeg as “an excellent scientist” and confirmed their multi-year professional relationship.

“I am friendly with her, as I am with many colleagues, but we do not have a longstanding personal friendship that would in any way prevent her from reviewing the citizen petition,” Urato stated.

A representative from the Department of Health and Human Services, the FDA’s parent agency, indicated the administration would provide a direct response to Urato regarding his proposal.

This past January, Urato received an appointment to the Centers for Disease Control and Prevention’s vaccine advisory committee, which Health Secretary Robert F. Kennedy Jr. has restructured to include multiple vaccine-skeptical members.

The antidepressant matter represents another divisive issue undertaken by Hoeg, a sports medicine doctor without prior government or administrative background.

Throughout the COVID-19 crisis, Hoeg gained recognition for opposing mask requirements, vaccination mandates, and similar public health policies. She collaborated on research with medical dissidents who later joined the current administration, including FDA Commissioner Marty Makary and the agency’s vaccine director, Dr. Vinay Prasad. All three have become prominent advocates for Kennedy’s agenda.

Prior to the pandemic, Hoeg had authored only a small number of medical publications, including research on health challenges facing ultramarathon athletes.

The Danish-American physician and distance runner played a key role in the Republican administration’s recent elimination of several childhood vaccine recommendations. This represents a policy shift she has long advocated to align American practices more closely with Denmark’s approach.

Similar to many vaccine critics, including Kennedy, Hoeg has expressed doubts about antidepressants, challenging both their safety profile and therapeutic value. Last July, she organized an FDA expert panel on SSRIs featuring Urato and nine additional medication critics.

“Never before in human history have we chemically altered developing babies like this, especially the developing fetal brain, and this is happening without any real public warning,” Urato stated during that gathering.

During a subsequent podcast appearance, Hoeg repeated many of Urato’s arguments.

“I think women should be informed about the potential risks so that they have time to come off SSRIs if they want to when they’re trying to get pregnant,” Hoeg explained to the Mom Wars podcast hosts.

FDA leadership generally refrains from public commentary on pending reviews to avoid suggesting decisions are based on personal viewpoints rather than scientific evidence.

Nevertheless, Hoeg has taken direct control of the SSRI evaluation, instructing FDA personnel that their proposed nine-month review schedule required shortening, according to informed sources.

Processing a citizen petition requires comprehensive examination of scientific documentation, legal considerations, and multiple procedural steps to ensure the agency’s ultimate determination can withstand court challenges.

“Apart from it serving FDA’s public health mission, there’s always going to be some concern about legal risk if the agency doesn’t take sufficient time to consider all the relevant data and arguments,” explained Patti Zettler, a former FDA legal counsel now teaching at Ohio State University’s law school.

Hoeg assumed leadership of the FDA’s drug division in December, taking charge during extraordinary organizational turmoil involving layoffs, voluntary departures, and management transitions. She represents the sixth individual to oversee the 5,000-employee center within the past year.

Staff members received no direct communication from Hoeg until a town hall meeting last month, where she expressed safety concerns about both SSRIs and injectable RSV medications for children — a drug category the FDA is reassessing at her direction. RSV is a respiratory infection that hospitalizes thousands of American children annually.

Antidepressant safety has faced scrutiny for decades, resulting in multiple label modifications including a black box warning about suicide risk in young people.

Current labeling for pregnant women identifies several confirmed safety concerns, including increased bleeding risks following delivery.

Physicians treating women with depression report they routinely discuss these risks with patients, weighing potential medication dangers against the serious consequences of depression relapse: self-injury, substance abuse, and other behaviors that harm both mothers and developing babies.

Researchers who have examined Urato’s SSRI petition indicate many studies claiming links to conditions like autism fail to account for other significant health variables. For instance, women with depression experience higher rates of smoking, diabetes, and family mental health histories that can all elevate developmental disorder risks.

“So how do we say that these outcomes are a result of the SSRI when all of these other factors are at play?” questioned Dr. Amritha Bhat, a University of Washington perinatal psychiatrist.

Bhat and fellow researchers endorse additional SSRI research and recognize potential medication drawbacks.

“But in the meantime we need to provide options to people that are struggling with these symptoms during pregnancy,” she emphasized. “We cannot just ask them to white knuckle their way through it.”